Connexion
Inscription
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
UCB
UCB
| Temps réel Euronext Bruxelles - 14:51:21 07/02/2023 | |
| 75.66 EUR | -0.81% |
Métier
| Santé | ||||
 | Recherche pharmaceutique et médicale | |||
| Produits pharmaceutiques | |||
| Produits pharmaceutiques | |||
| Biopharmacies | |||
UCB est une société biopharmaceutique qui se consacre à la recherche et au développement de nouveaux médicaments et de solutions innovantes destinés aux personnes atteintes de maladies graves du système nerveux central ou immunitaire.
Nombre d'employés : 8 561 personnes.
Nombre d'employés : 8 561 personnes.
Ventes par activité
| 2020 | 2021 | ||||
| Biopharmaceuticals | 5 052.00 | 94.5% | 5 471.00 | 94.7% | |
| EUR en Millions | |||||
Ventes par région
| 2020 | 2021 | ||||
| United States | 2 759.00 | 51.6% | 2 888.00 | 50% | |
| Japan | 379.00 | 7.1% | 561.00 | 9.7% | |
| Other Countries | 403.00 | 7.5% | 429.00 | 7.4% | |
| Germany | 339.00 | 6.3% | 335.00 | 5.8% | |
| Europe- Other (excluding Belgium) | 330.00 | 6.2% | 331.00 | 5.7% | |
| Spain | 192.00 | 3.6% | 202.00 | 3.5% | |
| France (including French Territories) | 164.00 | 3.1% | 172.00 | 3% | |
| Italy | 154.00 | 2.9% | 159.00 | 2.8% | |
| United Kingdom and Ireland | 148.00 | 2.8% | 150.00 | 2.6% | |
| China | 108.00 | 2% | 140.00 | 2.4% | |
| Global | 29.00 | 0.5% | 57.00 | 1% | |
| Belgium | 47.00 | 0.9% | 47.00 | 0.8% | |
| EUR en Millions | |||||
Dirigeants
| Nom | Titre |
| Jean-Christophe Tellier | Chief Executive Officer & Executive Director |
| Sandrine Dufour | Chief Financial Officer & Executive Vice President |
| Fiona du Monceau-de Hemptinne | Chairman |
| Iris Löw-Friedrich | Chief Medical Officer, EVP & Head-Development |
| Dhavalkumar Patel | Chief Scientific Officer & Executive VP |
| Herman de Prins | Chief Information Officer |
| Kirsten Lund Jurgensen | Executive VP, Head-Supply & Technology Unit |
| Albrecht de Graeve | Independent Director |
| Ulf Arne Wiinberg | Independent Director |
| Pierre L. Gurdjian | Independent Director |
| Actionnaires |
| Nom | Actions | % |
| Financière de Tubize SA | 68 333 981 | 35,1% |
| Wellington Management Co. LLP | 19 724 818 | 10,1% |
| Fidelity Management & Research Co. LLC | 6 216 870 | 3,20% |
| UCB SA | 5 331 781 | 2,74% |
| The Vanguard Group, Inc. | 3 376 787 | 1,74% |
| Norges Bank Investment Management | 2 887 682 | 1,48% |
| Amundi Asset Management SA (Investment Management) | 2 777 488 | 1,43% |
| Baillie Gifford & Co. | 1 943 338 | 1,00% |
| BlackRock Advisors (UK) Ltd. | 1 558 454 | 0,80% |
| Artisan Partners LP | 1 542 012 | 0,79% |
Coordonnées société
Allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Téléphone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : https://www.ucb.com/
BE-1070 Bruxelles, Bruxelles-Capitale
Téléphone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : https://www.ucb.com/
Places et indices
| - Compartiment A |
| - BEL 20 / Euronext 100, PEA, STOXX Europe 600 |
Codes boursiers
| - Code Bloomberg : | UCB:BB |
| - Code Reuters : | UCB.BR |
Secteur Biopharmacies
| Var. 1janv | Capi. (M$) | ||
 | |||
| UCB SA | 3.74% | 15 557 | |
| |||
| CSL LIMITED | 8.40% | 103 363 | |
| SAMSUNG BIOLOGICS CO.,LTD. | -1.71% | 45 550 | |
| BIOGEN INC. | 2.42% | 41 513 | |
| WUXI BIOLOGICS (CAYMAN) INC. | 6.10% | 34 193 | |
| CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. | 9.05% | 22 564 | |
| BIOMARIN PHARMACEUTICAL INC. | 8.42% | 20 849 | |
| BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. | 1.55% | 17 164 | |
| UCB | 3.70% | 15 557 | |
| WALVAX BIOTECHNOLOGY CO., LTD. | -1.64% | 9 308 | |
| BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED | -8.27% | 8 790 | |
| GRIFOLS, S.A. | 25.63% | 8 669 | |
| INNOVENT BIOLOGICS, INC. | 27.61% | 8 360 | |
| CELLTRION HEALTHCARE CO., LTD. | 2.24% | 7 586 | |
| SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | -22.06% | 7 334 | |
| SWEDISH ORPHAN BIOVITRUM AB (PUBL) | 9.41% | 6 580 | |
| APELLIS PHARMACEUTICALS, INC. | 6.77% | 6 099 | |
| HUALAN BIOLOGICAL ENGINEERING INC. | -2.25% | 5 942 | |
| BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. | -2.06% | 5 638 | |
| SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. | 19.57% | 4 728 | |
| SK BIOSCIENCE CO.,LTD. | 5.03% | 4 701 | |
Portefeuille de Marques
